头孢他啶阿维巴坦治疗碳青霉烯类耐药铜绿假单胞菌感染患者的疗效与安全性分析
DOI:
作者:
作者单位:

南京医科大学第一附属医院

作者简介:

通讯作者:

中图分类号:

基金项目:

江苏省卫生健康委科研课题


The efficacy and safety of ceftazidime avibactam versus polymyxin B for patients with carbapenem-resistant Pseudomonas aeruginosa infection
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:旨在评估头孢他啶阿维巴坦在碳青霉烯类耐药铜绿假单胞菌感染患者中与以多粘菌素B为基础的联合治疗相比的疗效和安全性。方法:回顾性分析2019年6月-2022年1月南京医科大学第一附属医院ICU内碳青霉烯类耐药铜绿假单胞菌感染患者,分为头孢他啶阿维巴坦组和多粘菌素B组,收集患者临床资料,包括性别、年龄、诊断、住院时间等基本信息,比较疗效指标包括细菌清除率、28天死亡率等,以及肝肾功能不全等不良反应的发生率。结果:共纳入55例,其中头孢他啶阿维巴坦组25例,多粘菌素B组30例,两组之间基本指标、细菌清除率、28天死亡率、不良反应差异均无统计学意义,头孢他啶阿维巴坦组住院时间长于多粘菌素B组(49 (34,78) vs26 (15.75,40.5), P=0.001<0.05),在抗生素联合应用方面较多粘菌素B组少。结论:与多粘菌素B相比,头孢他啶阿维巴坦在临床治愈、细菌清除率方面效果相似,不良反应方面无统计学差异,增加了临床用药的选择,有助于减轻公共卫生事业压力。

    Abstract:

    Objective To evaluate the efficacy and safety of ceftazidime avibactam compared with polymyxin based combination therapy in patients with carbapenem resistant Pseudomonas aeruginosa infection. Methods Retrospective analysis was carried out on the patients infected with carbapenem resistant Pseudomonas aeruginosa in the ICU of the First Affiliated Hospital of Nanjing Medical University from June 2019 to January 2022. They were divided into ceftazidime avibactam group and polymyxin B group. The clinical data of patients were collected, including basic information such as gender, age, diagnosis, and length of stay. The comparative efficacy indicators included bacterial clearance rate, 28-day mortality rate and the incidence of adverse reactions such as liver and kidney dysfunction. Results A total of 55 patients were included, including 25 patients in the ceftazidime avibactam group and 30 patients in the polymyxin B group. There was no statistically significant difference in basic indicators, bacterial clearance, 28-day mortality, and adverse reactions between the two groups. The length of hospital stay in the ceftazidime avibactam group was longer than that in the polymyxin B group (49 (34, 78) vs 26 (15.75, 40.5), P=0.001<0.05), and ceftazidime avibactam group has fewer antibiotic combinations than polymyxin B group. Conclusion Compared with polymyxin B, ceftazidime averbactam has similar effects in clinical cure and bacterial clearance, and there is no statistical difference in adverse reactions. It increases the choice of clinical drugs and helps to reduce the pressure on public health.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-03-09
  • 最后修改日期:2023-06-12
  • 录用日期:2023-08-09
  • 在线发布日期:
  • 出版日期: